Hyperhomocisteinemia, hypercysteinemia, glutamate excitotoxicity, taurine deficiency at hepatitis C
Abstract
Aim of investigation. An estimation of metabolic disorders related to chronic course of hepatitis C.
Material and methods. Total homocysteine (tHCy), total cysteine (tCys), total glutathione (tGSH) and free aminoacids (Asp, Asn, Glu, Gln, Tau, Ser) levels were measured by high-performance liquid chromatography in plasma of 55 hepatitis C patients and 14 healthy volunteers.
Results. Total statistical data processing at hepatitis C revealed: hyperhomocisteinemia (2,5 times increase in tHCy level), hypercysteinemia (1,5 times increase in tCys level), glutamate excitotoxicity (2,75 times increase in Glu level on a background of relative decrease of levels of tGSH and Gln), deficiency of taurine (level was decreased 1,4 times), increase of Gln, Asp, Asn, Ser levels 1,56, 1,75, 1,32, 1,4 times respectively. Data processing by nonnormal histogram plotting of substances plasma levels in hepatitis C patients revealed heterogeneity of pathochemistry of hepatitis C for tGSH, tCys and Gln. However in sets both with relatively low and high levels of these substances content of tHCy, Glu and Asp remains increased and reflects hyperhomocisteinemia and glutamate excitotoxicity phenomena. In patients with high content of tGSH and Gln in blood glutamate excitotoxicity was less expressed — levels of tHCy, Glu and Asp were increased to lesser degree, strong positive correlation between tGSH, Gln, tCys and Ser was marked.
Conclusion. Metabolic therapy can essentially decrease negative effect of metabolic disorders and increase efficacy of PEG-IFN-α in combination to ribavirin at hepatitis C treatment.
About the Authors
V. K. Pozdeev
Federal government-financed institution «Research Institute of Influenza», Ministry of healthcare of the Russian Federation
Russian Federation
Russian Federation
Pozdeev Vladimir K – MD, professor of biochemistry, research associate, Division of clinical and experimental investigations
197376, Saint-Petersburg, Prof. Popova street, 15/17
N. V. Pozdeev
Department of Medicine, Colorado State University
United States
United States
Pozdeyev Nikita V – MD, PhD, endocrine fellow
MS 8106, 12801 E. 17th Ave, RC1-South, 7th floor room 7103, Aurora, CO 80045
O. Ye. Nikitina
Federal government-financed institution «Research Institute of Influenza», Ministry of healthcare of the Russian Federation
Russian Federation
Russian Federation
Nikitina Olesya Ye – PhD, senior researcher, Division of clinical and experimental investigations
197376, Saint-Petersburg, Prof. Popova street, 15/17
References
1. Word Health Organization Initiative for vaccine research (IVR) Hepatitis C page. Available at: http://www.who. int/vaccine_research/diseases/viral_cancers/en/index2. html Accessed January 15, 2008.
2. Keating Gillian M., Curran Monique P. Peginterferon-2a (40 kD) plus ribavirin. A review of its use in the management of chronic hepatitis C. Drugs 2003; 63 (7):701-30.
3. Zeuzem S., Welsch C., Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23(1):23-8.
4. Oppenheim Y., Ban Y., Tomer Y. Interferon induced autoimmune thyroid disease (AITD): a model for human autoimmunity. Autoimmun Rev 2004; 3:388-93.
5. Головченко А.И. Проблемные вопросы диагностики и терапии хронического вирусного гепатита С. Сучасні медичні технології 2010; 2:132-6.
6. Pozdeev V.K., Pozdeyev N.V. Determination of total aminothiols and neuroactive amino acids in plasma by high performance liquid chromatography with fluorescence detection. Biochemistry (Mosc.) Suppl Ser B: Biomedical Chemistry 2010; 4(3):288-95.
7. Никитина О.Е., Поздеев В.К. Гомоцистеин и цистеин в плазме крови больных хроническим гепатитом С. Гастроэнтерол С.-Петербурга 2009; 2(3):60.
8. Ventura P., Rosa M.C., Abbati G., et al. Hyperhomocysteinaemia in chronic liver diseases: role of disease stage, vitamin status and methylenetetrahydrofolate reductase genetics. Liver Int 2005; 25:49-56.
9. Chwatko G., Jakubowski H. The determination of homocysteine-thiolactone in human plasma. Anal Biochem 2005; 337:271-7.
10. Ji С., Karlowitz N. Hyperhomocysteinemia, endoplasmatic reticulum stress, and alcoholic liver injury. World J Gastroenterol 2004; 10(12):1669-708.
11. Jacubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 2004; 61:470-87.
12. Moat S.J., Bao L., Fowler B. The molecular basis of cystathionine-beta-synthase (CBS) deficiency in UK and US patients with homocystinuria. Hum Mutat 2004; 23:206-10.
13. Поздеев В.К., Поздеев Н.В. Методы нейрохимических исследований в клинике. СПб: Реноме, 2013; 312 с.
14. Tagawa Tadayasu, Sengupta Shantanu, Chen Hong. Mechanisms for the formation of protein-bound homocysteine in human plasma. Biochem Biophys Res Communications 2000:277:668-74.
15. Биохимия: учебник / Под ред. Е.С.Северина. 5-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2013. 768 с.
16. Wang W., Rusin O., Xu X., et al. Detection of homocysteine and cysteine. J Am Chem Soc 2005; l(127):15949-58.
17. Droge W., Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J 1997; 11:1077-89.
18. Radzishevsky I., Sason H., Wolosker H. D-serine: physiology and pathology. Curr Opin Clin Nutr Metab Care 2013; 16(1):72-5.
19. Поздеев В.К. Роль нейромодуляторов — глицина, D-серина и таурина в формировании эпилептиформного синдрома. Рос нейрохирур журн им. А.Л. Поленова 2014; 6:366-70.
20. Olde Damink S.W., Jalan R., Dejong C.H. Interorgan ammonia trafficking in liver disease. Metab Brain Dis
21. :24(1):169-81.
22. Roth E. Immune and cell modulation by amino acids. Clin Nutr 2007; 26(5):535-44.
23. Bakalar B., Duska F., Pachl J., et al. Parenterally administered dipeptide alanylglutamine prevents worsening of insulin sensitivity in multiple trauma patients. Crit Care Med 2006; 34:381-6.
24. Spittler A., Sautner T., Gornikiewicz A., et al. Postoperative glycyl-glutamine infusion reduces immunosuppression: partial prevention of the surgery induced decrease in HLA-DR expression on monocytes. Clin Nutr 2001; 20(1):37-42.
25. Ярцев Е.И., Гольдберг Е.Д., Коменников Ю.А. Таурин (фармакологические и противолучевые свойства). М.: Медицина, 1975. 158 с.
26. Wright C.E., Tallan H.H., Lin Y.Y. Taurine: biological update. Ann Rev Biochem 1986; 55:427-53.
27. Huxtable R.J. Physiological action of taurine. Physiol Rev 1992; 72:101-63.
28. Pion P. D., Kittleson M.D., Thomas W.P. , et al. Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc 1992; 201(2):275-84.
29. Kumari N., Prentice H., Wu J-Y. Immune system, diabetes and the cardiovascular system / Taurine. Springer Science; New York; London. 2013; 8(1):19-30.
30. Wu H., Jin Y., Wei J., et al. Mode of action of taurine as a neuroprotector. Brain Res 2005; 1038:123-31.
31. Sturman J.A. Dietary taurine and reproduction and development. J Nutr 1991; 121(11):166-70.
32. Bernardini P. , Fisher E. Amino acid imbalance and hepatic encephalopathy. Ann Rev Nutr 1982; 2:419-54.
33. French E.D., Vezzani A., Whetsell Jr. W.O., et al. Antiexcitotoxic actions of taurine in the rat hippocampus studied in vivo and vitro. Adv Exp Med Biol 1986; 203:349-62.
34. Schaffer S.W, Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 2009; 87:91-9.
35. Gurujeyalakshmi G., Wang Y., Giri S.N. Suppression of bleomycin-induced nitric-oxide production in mice by taurine and niacin. Adv Exp Med Biol 2000; 483:545-61.
36. Park E., Alberti J., Quinn M.R., Schuller-Levis G. Taurine chloramines inhibits production of superoxide anion, IL-6 and IL-8 in activated human polymorphonuclear leukocytes. Adv Exp Med Biol 1998; 442:177-82.
37. Kontny A.K., Scczepanska K., Kowalczewski J., et al. The mechanism of taurine chloramine inhibition of cytokine (interleukin-6, interleukin-8) production by rheumatoid arthritis. Arthritis Rheum 2000; 43:2169-77.
38. Meister A., Anderson M.E. Glutathione. Annu Rev Biochem 1983; 52:711-60.
39. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999; 27(9-10):922-35.
40. Fernandez-Checa J.C., Kaplowitz N., Garcia-Ruiz C., et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997; 273(1, Pt 1):7-17.
41. Peristeris P. , Clark B.D., Gatti S., et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol 1992; 140(2):390-9.
42. Droge W., Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 2000; 59(4):595-600.
43. Le-Donne I., Rossi R., Colombo G., et al. Protein S-glutathionylation: a regulatory device from bacteria to humans. Trends Biochem Sci 2009; 34(2):85-96.
44. Foster M.W., Hess D.T., Stamler J.S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009; 15(9):391-404.
45. Kamerbeek N.M., Van Z.R., De B.M., et al. Molecular basis of glutathione reductase deficiency in human blood cells. Blood 2007; 109(8):3560-6.
46. Ristoff E., Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis 2007; 2:16-26.
47. Hesketh J. Nutrigenomics and selenium: Gene expression patterns, physiological, targets, and genetics. Ann Rev Nutr 2008; 28:157-77.
48. Leuschner U. Overlap syndromes. Atypical manifestations of autoimmune hepatitis. Dr Falk Pharma GmbH 2001; 44 p.
49. Ивашкин В.Т., Буеверов А.О. Перекрестные синдромы как атипичные проявления аутоиммунного гепатита. Клин перспективы гастроэнтерол гепатол 2003; 1:20-5.
50. Shintani Y., Fujie H., Miyoshi H., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840-8.
51. Zekry A., McHutchinson J.G., Diehl A.M. Insulin resistance and steatosis in hepatitis C virus infection. Gut
52. ; 54(7):903-6.
53. Mizuta T., Kawaguchi Y., Eguchi Y., et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010; 5(1):183-9.
54. Enjoji M., Kohjima M., Kotoh K., Nakamuta M. Metabolic disorders and steatosis in patients with chronic hepatitis C: Metabolic strategies for antiviral treatments. Int J Hepatol 2012; 2012: Article ID 264017, 7 p.
55. Marchesini G., Brizi M., Blanchi G., et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358:893-4.
56. Trappoliere M., Tuccillo C., Federico A., et al. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 2005;9:299-304.
57. Cravo M.L., Gloria L.M., Selhub J., et al. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 1996:63(2):220-4.
58. Karakuła H., Opolska A., Kowal A., et al. Does diet affect our mood? The significance of folic acid and homocysteine. Pol Merkur Lekarski 2009; 26(152):136-41.
59. Fennessy F.M., Moneley D.S., Wang J.H., et al. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation 2003; 107(3):410-5.
60. Nemmiche S., Chabane-Sari D., Guiraud P. Role of α-tocopherol in cadmium-induced oxidative stress in Wistar rat’s blood, live and brain. Chem Biol Interact 2007; 170:221-30.
61. Yasutake K., Kohjima M., Kotoh K., et al. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(7):1756-67.
62. McKenzie R.C., Rafferty T.S., Beckett G.J. Selenium: an essential element for immune function. Immunol Today 1998; 19:342-5.
63. Whitacre M.E. Selenium and mitochondrial integrity in the pancreas of the chick. J Nutr 1983; 113(10):1972-83.
64. Скальный А.В., Рудаков И.А. Биоэлементы в медицине: Биология. М.: Мир, 2004; 272 с.
65. Ahn C.S. Effect of taurine supplementation on plasma homocysteine levels of the middle-aged korean women. Adv Exp Med Biol 2009; 643:415-22.
66. Lourenco R., Camilo M.E. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr Hosp 2002; 17(6):262-70.
67. Loguercio C., De Simone T., Federico A., et al. Gutliver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97:2144-6.
68. Poordaad F., Lawitz E., Kowdley K.V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368:45-53.
69. Бацких С.Н. Безинтерфероновая терапия хронического гепатита С: смена препаратов или новая парадигма лечения? Рос журн гастроэнтерол гепатол колопроктол 2014; 24(4):23-31.
Review
For citations:
Pozdeev V.K., Pozdeev N.V., Nikitina O.Ye. Hyperhomocisteinemia, hypercysteinemia, glutamate excitotoxicity, taurine deficiency at hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(3):49-60. (In Russ.)
Views:
176
Email this article 
